Literature DB >> 18536655

Expression of basal keratins and vimentin in breast cancers of young women correlates with adverse pathologic parameters.

Maureen Hong-Sing Chen1, George Wai-Cheong Yip, Gary Man-Kit Tse, Takuya Moriya, Philip Chi-Wai Lui, Mar-Lwin Zin, Boon-Huat Bay, Puay-Hoon Tan.   

Abstract

Previous studies have suggested that breast cancer in young women has more aggressive biological features and poorer prognosis. However, the role of biological markers in these patients is not well understood. We aimed to learn more about this disease in a cohort of 125 young women from Singapore, Japan and Hong Kong, aged 35 years or less, with invasive breast cancer by evaluating the expression of vimentin and the basal cytokeratins CK14, CK5/6 and 34 beta E12. Both standard paraffin sections and tissue microarrays were used in the immunohistochemical evaluation of expression patterns of these four biological markers. CK5/6, CK14, vimentin and 34 beta E12, in increasing order of proportion, were detected in invasive carcinomas. Basal cytokeratins and vimentin showed significant inverse relationship with estrogen and progesterone receptor status while CK14 expression was found to be directly associated with c-erbB2 status. Basal cytokeratins and vimentin immunoreactivities were directly associated with CD117 and EGFR expression. Vimentin and 34 beta E12 immunopositivity correlated with tumor size, while vimentin was associated with higher histological grade. Our findings are in concert with reports that expression of basal cytokeratins and vimentin is correlated with adverse pathological parameters.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18536655     DOI: 10.1038/modpathol.2008.90

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  16 in total

1.  ABCA2 transporter deficiency reduces incidence of TRAMP prostate tumor metastasis and cellular chemotactic migration.

Authors:  Jody T Mack; Kristi L Helke; Gabrielle Normand; CoDanielle Green; Danyelle M Townsend; Kenneth D Tew
Journal:  Cancer Lett       Date:  2010-10-30       Impact factor: 8.679

Review 2.  Molecular morphological approach to the pathological study of development and advancement of human breast cancer.

Authors:  Takuya Moriya; Naoki Kanomata; Yuji Kozuka; Hisashi Hirakawa; Izo Kimijima; Michio Kimura; Mika Watanabe; Hironobu Sasano; Takanori Ishida; Noriaki Ohuchi; Jun-Ichi Kurebayashi; Hiroshi Sonoo
Journal:  Med Mol Morphol       Date:  2010-08-04       Impact factor: 2.309

3.  Cyclooxygenase-2 promotes ovarian cancer cell migration and cisplatin resistance via regulating epithelial mesenchymal transition.

Authors:  Lin Deng; Ding-Qing Feng; Bin Ling
Journal:  J Zhejiang Univ Sci B       Date:  2020 Apr.       Impact factor: 3.066

4.  Proteomic profiling of lipid rafts in a human breast cancer model of tumorigenic progression.

Authors:  Joseph A Caruso; Paul M Stemmer
Journal:  Clin Exp Metastasis       Date:  2011-05-01       Impact factor: 5.150

5.  Withaferin A inhibits experimental epithelial-mesenchymal transition in MCF-10A cells and suppresses vimentin protein level in vivo in breast tumors.

Authors:  Joomin Lee; Eun-Ryeong Hahm; Adam I Marcus; Shivendra V Singh
Journal:  Mol Carcinog       Date:  2013-11-30       Impact factor: 4.784

6.  Platform-independent and label-free quantitation of proteomic data using MS1 extracted ion chromatograms in skyline: application to protein acetylation and phosphorylation.

Authors:  Birgit Schilling; Matthew J Rardin; Brendan X MacLean; Anna M Zawadzka; Barbara E Frewen; Michael P Cusack; Dylan J Sorensen; Michael S Bereman; Enxuan Jing; Christine C Wu; Eric Verdin; C Ronald Kahn; Michael J Maccoss; Bradford W Gibson
Journal:  Mol Cell Proteomics       Date:  2012-03-26       Impact factor: 5.911

7.  Luminal and basal-like breast cancer cells show increased migration induced by hypoxia, mediated by an autocrine mechanism.

Authors:  Melanie J Voss; Mischa F Möller; Desmond G Powe; Bernd Niggemann; Kurt S Zänker; Frank Entschladen
Journal:  BMC Cancer       Date:  2011-05-02       Impact factor: 4.430

8.  Does vimentin help to delineate the so-called 'basal type breast cancer'?

Authors:  Renata U Kusinska; Radzislaw Kordek; Elzbieta Pluciennik; Andrzej K Bednarek; Janusz H Piekarski; Piotr Potemski
Journal:  J Exp Clin Cancer Res       Date:  2009-08-20

9.  Withania somnifera root extract inhibits mammary cancer metastasis and epithelial to mesenchymal transition.

Authors:  Zhen Yang; Anapatricia Garcia; Songli Xu; Doris R Powell; Paula M Vertino; Shivendra Singh; Adam I Marcus
Journal:  PLoS One       Date:  2013-09-12       Impact factor: 3.240

10.  Biomarkers for Basal-like Breast Cancer.

Authors:  Jennifer R Choo; Torsten O Nielsen
Journal:  Cancers (Basel)       Date:  2010-05-28       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.